These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 26100980)

  • 1. High-mobility group box 1 in multiple sclerosis.
    Sternberg Z; Sternberg D; Chichelli T; Drake A; Patel N; Kolb C; Chadha K; Yu J; Hojnacki D
    Immunol Res; 2016 Apr; 64(2):385-91. PubMed ID: 26100980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease modifying drugs modulate endogenous secretory receptor for advanced glycation end-products, a new biomarker of clinical relapse in multiple sclerosis.
    Sternberg Z; Sternberg D; Drake A; Chichelli T; Yu J; Hojnacki D
    J Neuroimmunol; 2014 Sep; 274(1-2):197-201. PubMed ID: 25064498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of high mobility group box protein 1 (HMGB1) in peripheral blood from patients with multiple sclerosis.
    Malhotra S; Fissolo N; Tintoré M; Wing AC; Castilló J; Vidal-Jordana A; Montalban X; Comabella M
    J Neuroinflammation; 2015 Mar; 12():48. PubMed ID: 25879961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fingolimod anti-inflammatory and neuroprotective effects modulation of RAGE axis in multiple sclerosis patients.
    Sternberg Z; Kolb C; Chadha K; Nir A; Nir R; George R; Johnson J; Yu J; Hojnacki D
    Neuropharmacology; 2018 Mar; 130():71-76. PubMed ID: 29197515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does the Serum Expression Level of High-Mobility Group Box 1 (HMGB1) in Multiple Sclerosis Patients have a Relationship with Physical and Psychological Status? A 12-Month Follow-Up Study on Newly Diagnosed MS Patients.
    Sharafkhah M; Mosayebi G; Massoudifar A; Seddigh SH; Abdolrazaghnejad A; Alamdara MA; Mokarian P; Mohammadbeigi A; Ebrahimi-Monfared M
    Neurol India; 2022; 70(1):238-248. PubMed ID: 35263889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decreased level of sRAGE in the cerebrospinal fluid of multiple sclerosis patients at clinical onset.
    Glasnović A; Cvija H; Stojić M; Tudorić-Đeno I; Ivčević S; Romić D; Tičinović N; Vuletić V; Lazibat I; Grčević D
    Neuroimmunomodulation; 2014; 21(5):226-33. PubMed ID: 24603633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma high-mobility group box 1 protein is a potential marker for neuromyelitis optica.
    Wang KC; Tsai CP; Lee CL; Chen SY; Chin LT; Chen SJ
    Neuroscience; 2012 Dec; 226():510-6. PubMed ID: 23122444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating levels of soluble receptor for advanced glycation end products and ligands of the receptor for advanced glycation end products in patients with acute liver failure.
    Basta G; Del Turco S; Navarra T; Lee WM;
    Liver Transpl; 2015 Jun; 21(6):847-54. PubMed ID: 25825217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High mobility group box 1 levels in large vessel vasculitis are not associated with disease activity but are influenced by age and statins.
    de Souza AW; van der Geest KS; Brouwer E; Pinheiro FA; Oliveira AC; Sato EI; Andrade LE; Bijl M; Westra J; Kallenberg CG
    Arthritis Res Ther; 2015 Jun; 17(1):158. PubMed ID: 26062541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of High-mobility group box 1 levels and multiple sclerosis: A systematic review and meta-analysis.
    Zhen C; Wang Y; Li D; Zhang W; Zhang H; Yu X; Wang X
    Mult Scler Relat Disord; 2019 Jun; 31():87-92. PubMed ID: 30953953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus.
    Bobek D; Grčević D; Kovačić N; Lukić IK; Jelušić M
    Pediatr Rheumatol Online J; 2014; 12():50. PubMed ID: 25516724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HMGB1 as a potential new marker of disease activity in patients with multiple sclerosis.
    Bucova M; Majernikova B; Durmanova V; Cudrakova D; Gmitterova K; Lisa I; Klimova E; Kluckova K; Buc M
    Neurol Sci; 2020 Mar; 41(3):599-604. PubMed ID: 31728855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low glucose degradation product peritoneal dialysis regimen is associated with lower plasma EN-RAGE and HMGB-1 proinflammatory ligands of receptor for advanced glycation end products.
    Opatrna S; Popperlova A; Kalousová M; Zima T
    Ther Apher Dial; 2014 Jun; 18(3):309-16. PubMed ID: 24965297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preliminary study of high mobility group box chromosomal protein 1(HMGB1) in ankylosing spondylitis patients.
    Chen Y; Sun W; Li S; Ni J; Su Y; Wang C; Luo X; Tu W; Shen G; Gong F; Zheng F; Dong L
    Clin Exp Rheumatol; 2015; 33(2):187-94. PubMed ID: 25602579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble Forms and Ligands of the Receptor for Advanced Glycation End-Products in Patients with Acute Respiratory Distress Syndrome: An Observational Prospective Study.
    Jabaudon M; Blondonnet R; Roszyk L; Pereira B; Guérin R; Perbet S; Cayot S; Bouvier D; Blanchon L; Sapin V; Constantin JM
    PLoS One; 2015; 10(8):e0135857. PubMed ID: 26274928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical use of high mobility group box 1 and the receptor for advanced glycation end products in the prognosis and risk stratification of heart failure: a literature review.
    Marsh AM; Nguyen AH; Parker TM; Agrawal DK
    Can J Physiol Pharmacol; 2017 Mar; 95(3):253-259. PubMed ID: 28092162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the receptor for advanced glycation end products, a target for high mobility group box 1 protein, and its role in chronic recalcitrant rhinosinusitis with nasal polyps.
    Dzaman K; Szczepanski MJ; Molinska-Glura M; Krzeski A; Zagor M
    Arch Immunol Ther Exp (Warsz); 2015 Jun; 63(3):223-30. PubMed ID: 25503556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positive association of serum levels of advanced glycation end products and high mobility group box-1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
    Nakamura T; Sato E; Fujiwara N; Kawagoe Y; Ueda Y; Suzuki T; Yamada S; Takeuchi M; Fukami K; Ueda S; Adachi H; Matsui T; Okuda S; Yamagishi S
    Metabolism; 2009 Nov; 58(11):1624-8. PubMed ID: 19604520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of high mobility group box-1 in the lung tissue and serum of patients with pulmonary tuberculosis].
    Yang XM; Yang H
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jul; 36(7):497-500. PubMed ID: 24262084
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations.
    de Souza AW; Perazzio SF; de França NR; Andrade LE; Bijl M; Westra J; Kallenberg CG
    Rheumatology (Oxford); 2015 Dec; 54(12):2151-5. PubMed ID: 26170374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.